Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742475 | 0.80 | HRH3 (0.48) | HRH3GPR119 | |
| SCHEMBL1744637 | 0.79 | HRH3 (0.45) | HRH3GPR119 | |
| SCHEMBL1744639 | 0.79 | PANK3 (0.48) | HRH3GPR119 | |
| SCHEMBL27921240 | 0.77 | TLR9 (0.44) | HRH3TLR9TLR8TLR7RET | |
| SCHEMBL1743145 | 0.72 | TLR9 (0.46) | HRH3GPR119TLR9TLR8TLR7 | |
| SCHEMBL1742769 | 0.71 | HRH3 (0.54) | HRH3TLR9TLR8TLR7RET | |
| SCHEMBL27728017 | 0.70 | HRH3 (0.45) | HRH3TLR9TLR8TLR7RET | |
| SCHEMBL1744282 | 0.69 | HRH3 (0.49) | HRH3 | |
| SCHEMBL1743090 | 0.69 | TLR9 (0.52) | HRH3TLR9TLR8TLR7RET | |
| SCHEMBL1742814 | 0.68 | HRH3 (0.52) | HRH3TLR9TLR8TLR7RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885GPR119 198/4885TLR9 1791/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885GPR119 198/4885TLR9 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.